INDIVIOR PHARMACEUTICALS INC (INDV) Stock Fundamental Analysis

NASDAQ:INDV • US45579U1097

32.93 USD
-0.96 (-2.83%)
At close: Feb 23, 2026
32.93 USD
0 (0%)
After Hours: 2/23/2026, 5:39:11 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

INDV gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. INDV has an excellent profitability rating, but there are some minor concerns on its financial health. INDV scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • INDV had positive earnings in the past year.
  • In the past year INDV had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: INDV reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: INDV reported negative operating cash flow in multiple years.
INDV Yearly Net Income VS EBIT VS OCF VS FCFINDV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

  • INDV has a better Return On Assets (8.62%) than 89.58% of its industry peers.
  • INDV has a better Return On Invested Capital (50.62%) than 100.00% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for INDV is significantly above the industry average of 12.96%.
  • The last Return On Invested Capital (50.62%) for INDV is above the 3 year average (43.06%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROIC 50.62%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
INDV Yearly ROA, ROE, ROICINDV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300 400

1.3 Margins

  • INDV has a better Profit Margin (10.34%) than 84.38% of its industry peers.
  • INDV's Profit Margin has declined in the last couple of years.
  • INDV has a Operating Margin of 24.49%. This is amongst the best in the industry. INDV outperforms 91.67% of its industry peers.
  • In the last couple of years the Operating Margin of INDV has remained more or less at the same level.
  • INDV has a Gross Margin of 85.51%. This is amongst the best in the industry. INDV outperforms 89.06% of its industry peers.
  • In the last couple of years the Gross Margin of INDV has remained more or less at the same level.
Industry RankSector Rank
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
INDV Yearly Profit, Operating, Gross MarginsINDV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • INDV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • INDV has less shares outstanding than it did 1 year ago.
  • INDV has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for INDV is higher compared to a year ago.
INDV Yearly Shares OutstandingINDV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
INDV Yearly Total Debt VS Total AssetsINDV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • INDV has an Altman-Z score of 2.69. This is not the best score and indicates that INDV is in the grey zone with still only limited risk for bankruptcy at the moment.
  • INDV's Altman-Z score of 2.69 is fine compared to the rest of the industry. INDV outperforms 67.71% of its industry peers.
  • INDV has a debt to FCF ratio of 2.68. This is a good value and a sign of high solvency as INDV would need 2.68 years to pay back of all of its debts.
  • INDV's Debt to FCF ratio of 2.68 is amongst the best of the industry. INDV outperforms 93.23% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Altman-Z 2.69
ROIC/WACC5.32
WACC9.51%
INDV Yearly LT Debt VS Equity VS FCFINDV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • INDV has a Current Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • INDV has a worse Current ratio (0.96) than 85.42% of its industry peers.
  • INDV has a Quick Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.79, INDV is doing worse than 81.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.79
INDV Yearly Current Assets VS Current LiabilitesINDV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • INDV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 256.36%, which is quite impressive.
  • The earnings per share for INDV have been decreasing by -53.19% on average. This is quite bad
  • Looking at the last year, INDV shows a decrease in Revenue. The Revenue has decreased by -0.25% in the last year.
  • Measured over the past years, INDV shows a quite strong growth in Revenue. The Revenue has been growing by 8.64% on average per year.
EPS 1Y (TTM)256.36%
EPS 3Y-75.32%
EPS 5Y-53.19%
EPS Q2Q%33.33%
Revenue 1Y (TTM)-0.25%
Revenue growth 3Y14.52%
Revenue growth 5Y8.64%
Sales Q2Q%2.28%

3.2 Future

  • INDV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.61% yearly.
  • INDV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.36% yearly.
EPS Next Y440.8%
EPS Next 2Y161.63%
EPS Next 3Y95.81%
EPS Next 5Y37.61%
Revenue Next Year3.67%
Revenue Next 2Y-0.17%
Revenue Next 3Y1.6%
Revenue Next 5Y1.36%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
INDV Yearly Revenue VS EstimatesINDV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
INDV Yearly EPS VS EstimatesINDV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 16.80, which indicates a correct valuation of INDV.
  • Based on the Price/Earnings ratio, INDV is valued cheaper than 86.46% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.64. INDV is valued slightly cheaper when compared to this.
  • The Price/Forward Earnings ratio is 10.93, which indicates a very decent valuation of INDV.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 87.50% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.75. INDV is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 16.8
Fwd PE 10.93
INDV Price Earnings VS Forward Price EarningsINDV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 84.38% of the companies in the same industry are more expensive than INDV, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, INDV is valued cheaply inside the industry as 80.73% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 34.26
EV/EBITDA 13.04
INDV Per share dataINDV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • INDV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • INDV has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as INDV's earnings are expected to grow with 95.81% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y161.63%
EPS Next 3Y95.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • INDV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INDIVIOR PHARMACEUTICALS INC

NASDAQ:INDV (2/23/2026, 5:39:11 PM)

After market: 32.93 0 (0%)

32.93

-0.96 (-2.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30
Earnings (Next)02-26
Inst Owners92.33%
Inst Owner Change-70.47%
Ins Owners3.78%
Ins Owner Change31.01%
Market Cap4.11B
Revenue(TTM)1.18B
Net Income(TTM)122.00M
Analysts84.62
Price Target46.48 (41.15%)
Short Float %10.17%
Short Ratio5.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)81.89%
Min EPS beat(2)71.47%
Max EPS beat(2)92.31%
EPS beat(4)4
Avg EPS beat(4)70.49%
Min EPS beat(4)45.92%
Max EPS beat(4)92.31%
EPS beat(8)6
Avg EPS beat(8)12.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.31%
Min Revenue beat(2)17.53%
Max Revenue beat(2)21.1%
Revenue beat(4)4
Avg Revenue beat(4)14.97%
Min Revenue beat(4)8.6%
Max Revenue beat(4)21.1%
Revenue beat(8)5
Avg Revenue beat(8)7.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.33%
PT rev (3m)24.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.31%
EPS NY rev (1m)0%
EPS NY rev (3m)79.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.81%
Valuation
Industry RankSector Rank
PE 16.8
Fwd PE 10.93
P/S 3.48
P/FCF 34.26
P/OCF 22.84
P/B N/A
P/tB N/A
EV/EBITDA 13.04
EPS(TTM)1.96
EY5.95%
EPS(NY)3.01
Fwd EY9.15%
FCF(TTM)0.96
FCFY2.92%
OCF(TTM)1.44
OCFY4.38%
SpS9.45
BVpS-1.66
TBVpS-1.67
PEG (NY)0.04
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROCE 64.08%
ROIC 50.62%
ROICexc 3805.17%
ROICexgc 5707.75%
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
FCFM 10.17%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)54.5%
ROCE(5y)38.6%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Debt/EBITDA 0.97
Cap/Depr 230.77%
Cap/Sales 5.08%
Interest Coverage 250
Cash Conversion 57.14%
Profit Quality 98.36%
Current Ratio 0.96
Quick Ratio 0.79
Altman-Z 2.69
F-Score8
WACC9.51%
ROIC/WACC5.32
Cap/Depr(3y)163.83%
Cap/Depr(5y)132.28%
Cap/Sales(3y)2.67%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)256.36%
EPS 3Y-75.32%
EPS 5Y-53.19%
EPS Q2Q%33.33%
EPS Next Y440.8%
EPS Next 2Y161.63%
EPS Next 3Y95.81%
EPS Next 5Y37.61%
Revenue 1Y (TTM)-0.25%
Revenue growth 3Y14.52%
Revenue growth 5Y8.64%
Sales Q2Q%2.28%
Revenue Next Year3.67%
Revenue Next 2Y-0.17%
Revenue Next 3Y1.6%
Revenue Next 5Y1.36%
EBIT growth 1Y8.24%
EBIT growth 3Y11.69%
EBIT growth 5Y7.28%
EBIT Next Year1050.98%
EBIT Next 3Y148.27%
EBIT Next 5Y64.69%
FCF growth 1Y236.36%
FCF growth 3Y-74.97%
FCF growth 5Y-48.94%
OCF growth 1Y446.15%
OCF growth 3Y-53.28%
OCF growth 5Y-24.93%

INDIVIOR PHARMACEUTICALS INC / INDV FAQ

What is the fundamental rating for INDV stock?

ChartMill assigns a fundamental rating of 6 / 10 to INDV.


What is the valuation status of INDIVIOR PHARMACEUTICALS INC (INDV) stock?

ChartMill assigns a valuation rating of 9 / 10 to INDIVIOR PHARMACEUTICALS INC (INDV). This can be considered as Undervalued.


What is the profitability of INDV stock?

INDIVIOR PHARMACEUTICALS INC (INDV) has a profitability rating of 7 / 10.


How financially healthy is INDIVIOR PHARMACEUTICALS INC?

The financial health rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 4 / 10.


Is the dividend of INDIVIOR PHARMACEUTICALS INC sustainable?

The dividend rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 0 / 10 and the dividend payout ratio is 0%.